Book a meeting
DO-BO

What Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?

How can AI revolutionize Market Access, and what does it take to drive successful change in pharma? Tune into the latest episode of MAP, the Market Access Podcast, where our host Dr. Stefan Walzer and Jan Kroschinski, an expert in digital transformation, will delve into change management and AI adoption in pharma.

Follow along as they explore how AI can streamline processes like dossier writing and HTA submissions, while tackling resistance to change. Discover strategies for effective AI adoption, leadership engagement, and risk vs. opportunity – how to shift from fear-based thinking to opportunity-driven AI adoption. Get ahead of the AI curve with this insightful discussion!

Related

Wie finanziert Deutschland Gesundheitsinnovation, ohne den Patientenzugang zu gefährden, Afschin Gandjour?

By

Stefan Walzer

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]

What lessons can Market Access teams learn from an Olympic medalist, Livia Altmann?

By

Stefan Walzer

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and “Human Intelligence 2.0” expert. Together, they explore how […]

How Are UK NICE and US IRA/MFN Rewriting Global Pharma Pricing, Sreeram Ramagopalan?

By

Stefan Walzer

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly […]